Australia's national lung screening program gets its clinical guidelines

Australia now has published clinical guidelines for its National Lung Cancer Screening Program, the targeted low-dose CT programme the federal government launched in July 2025 [s1]. The guidelines, issued through the Medical Journal of Australia, set out who is eligible, how scans are ordered and read, and how results and incidental findings are managed across the screening pathway [s1][s2].

The programme matters because of what it targets. Lung cancer is the leading cause of cancer mortality in Australia, and it is often diagnosed late, when treatment options are narrow [s1]. Screening high-risk people with low-dose CT is the intervention with the strongest trial evidence for catching the disease early enough to change that, and Australia is among the first countries to build it into a national, publicly funded programme rather than leaving it to opportunistic testing.

Who is eligible

Eligibility is risk-based, using criteria recommended by the Medical Services Advisory Committee. The programme targets people between 50 and 70 years of age who have no signs or symptoms suggestive of lung cancer, who currently smoke or quit within the past 10 years, and who have a history of tobacco cigarette smoking of at least 30 pack-years [s1]. A pack-year is one pack of cigarettes a day for a year, so a 30 pack-year threshold captures, for example, a pack a day for 30 years or two packs a day for 15.

Those thresholds are deliberately narrow. Screening a lower-risk population dilutes the benefit and raises the share of results that are false alarms, so lung-screening programmes worldwide restrict eligibility to older, heavier smokers in whom the disease is common enough that finding it early outweighs the harms of scanning. The symptom exclusion matters too: screening is for people who feel well. Someone with symptoms suggestive of lung cancer needs diagnostic assessment, not a screening scan.

How it works

Screening is delivered by low-dose CT, a scan that uses a fraction of the radiation of a standard chest CT. The government created two mandatory bulk-billing Medicare Benefit Schedule items to cover the scans, meaning eligible participants face no out-of-pocket cost: a screening low-dose CT performed at baseline and then every two years, and an interval low-dose CT for any follow-up needed during the two-yearly screening period based on the earlier scan's results [s1]. Bulk-billing — where the provider bills Medicare directly and the patient pays nothing — is central to the design, since cost is one of the barriers that keeps screening from reaching the people who need it most.

The two-yearly, or biennial, interval sits between the annual schedule used in some other programmes and less frequent testing; it reflects the balance the advisory process struck between catching cancers early and limiting radiation exposure and false-positive workups [s1]. Scans are read and reported under the programme's nodule-management protocol, which standardises how the small lung nodules that CT frequently detects are classified and followed, so that a benign nodule does not trigger an unnecessary cascade of tests [s1]. Participants are enrolled in the National Cancer Screening Register, the national system that also underpins Australia's bowel and cervical screening programmes and tracks who is due for their next scan [s1].

Smoking-cessation support is built into the pathway rather than bolted on: the guidelines state that cessation supports are to be offered to all potential participants by healthcare providers across the screening and assessment pathway [s1]. That reflects a lesson from screening research — the screening visit is a moment when people are receptive to quitting, and cessation delivers a health benefit that screening alone cannot.

What the guidelines do and do not settle

The guidelines are an operational document. They cover assessing eligibility, enrolling participants in the register, completing and fulfilling low-dose CT requests, assessing and reporting scan results, managing scan outcomes and actionable additional findings, and communicating results back to participants [s1]. Incidental findings are a known feature of chest CT — the scan can reveal coronary artery calcification or other abnormalities unrelated to lung cancer — and having a defined protocol for handling them is part of running a programme responsibly rather than generating anxiety and downstream testing.

What guidelines cannot settle in advance is reach. The hard problem for any lung-screening programme is participation: eligible people, many of them current smokers, are precisely the group that engages least with preventive health services. Whether the programme narrows lung-cancer mortality will depend less on the scan itself — the trial evidence for low-dose CT is established — than on how many eligible Australians enrol, return for their two-yearly scans, and complete follow-up when a nodule is found.

The figures here are the programme's own parameters, published in its guidelines: ages 50 to 70, a 30 pack-year smoking history, current smoking or having quit within 10 years, and two-yearly low-dose CT [s1]. The evidence on whether a national programme built on them changes outcomes will come from the register data over the years ahead.

Sources

• [s1] Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in Australia — Medical Journal of Australia, 224(7):e70234, 2026.
• [s2] Program Guidelines for the National Lung Cancer Screening Program (full text) — PubMed Central, U.S. National Library of Medicine, 2026.